Kardigan, Inc.
KARD evidence brief
What we can confirm
- BioSniper Score:
- 9.6 / 10
- Market Cap:
- $2.02B
What it means
What to watch
Prepared research question
What matters most for KARD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KARD
Kardigan is a clinical-stage precision therapeutics company developing targeted treatments for cardiovascular diseases with no approved therapies, currently advancing three late-stage programs.
Key risk: No revenue yet
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$2.02B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials for Kardigan, Inc..
Kardigan is a clinical-stage precision therapeutics company developing targeted treatments for cardiovascular diseases with no approved therapies, currently advancing three late-stage programs.
- Kardigan is a clinical-stage precision therapeutics company developing medicines for cardiovascular diseases where no approved treatments exist [sec_mda · as of 2026-08-11].
- The company has three late-stage programs: Danicamtiv (genetic DCM), Ataciguat (moderate CAVS), and Tonlamarsen (post-hospitalization ASH) [sec_mda · as of 2026-08-11].
- As of 2026-06-30, Kardigan reported cash & equivalents of $384.0M, net income of -$116.2M, and shareholders' equity of $615.5M [sec].
- Kardigan has not generated any revenue from product sales and has incurred significant operating losses since inception [sec · filed 2026-06-11].
- The company anticipates sharing topline data from the Phase 2b portion of the KINSHIP-DCM trial for Danicamtiv in the first half of 2027 [sec · filed 2026-06-11].
What works
- Kardigan has a substantial cash position of $384.0M as of 2026-06-30, providing a multi-year runway to advance its pipeline [sec].
- The company targets high-need cardiovascular indications with no approved therapies, potentially creating new standards of care [sec_mda · as of 2026-08-11].
- Kardigan's management team includes leaders from MyoKardia, indicating experienced leadership in cardiovascular drug development [sec_mda · as of 2026-08-11].
What to weigh
- Kardigan has not yet generated any revenue from product sales and has incurred significant operating losses, with a net loss of $116.2M for the six months ended June 30, 2026 [sec].
- The company's business is highly dependent on the success of its three product candidates; failure of any could materially harm the business [sec · filed 2026-06-11].
- Kardigan will require additional funding to finance operations if its current cash is insufficient, and inability to raise capital could force delays or reductions in programs [sec · filed 2026-06-11].
From the filings
Quoted directly from source documents.
Kardigan is a clinical-stage precision therapeutics company developing medicines for cardiovascular diseases with no approved treatments.
“a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist.”
SEC MD&A · August 11, 2026
Kardigan has three late-stage programs: Danicamtiv, Ataciguat, and Tonlamarsen.
“We have three late-stage programs, Danicamtiv, Ataciguat, and Tonlamarsen, in clinical development for indications for which no approved therapies currently exist.”
SEC MD&A · August 11, 2026
Kardigan has not generated any revenue from product sales and has incurred significant operating losses.
“Since our inception, we have not generated any revenue from product sales or other sources and have incurred significant operating losses and negative cash flows from our operations.”
SEC filings · June 11, 2026
Kardigan anticipates sharing topline data from the Phase 2b portion of the KINSHIP-DCM trial in the first half of 2027.
“We anticipate sharing topline data from the Phase 2b portion of theKINSHIP-DCMin the first half of 2027.”
SEC filings · June 11, 2026
Catalyst timeline
- 2026-02-13 · Phase 2b/3 trial start for Danicamtiv in genetic DCM — Adaptive, randomized, double-blind, placebo-controlled study to assess efficacy and safety in symptomatic genetic and familial dilated cardiomyopathy.
- 2026-06-23 · Phase 2b trial start for Tonlamarsen in ASH — Randomized, double-blind, placebo-controlled study to evaluate efficacy and safety in participants with recent hospitalization and acute severe hypertension.
- 2026-08-26 · Open-label extension study start for Danicamtiv — Long-term safety and efficacy study in adults with symptomatic genetic and familial dilated cardiomyopathy.
Risks & what to watch (3)›
Key risks
- No revenue yet — Kardigan has not generated any product revenue and relies on funding; net loss of $116.2M as of 2026-06-30 [sec].
- Pipeline concentration risk — Business depends on success of Danicamtiv, Ataciguat, and Tonlamarsen; failure of any could materially harm the company [sec · filed 2026-06-11].
- Need for additional funding — If current cash is insufficient, Kardigan will require more capital; inability to raise funds could delay or reduce programs [sec · filed 2026-06-11].
What to watch
- Topline data from the Phase 2b portion of the KINSHIP-DCM trial for Danicamtiv, expected in the first half of 2027 [sec · filed 2026-06-11].
- Progress of the Phase 2b trial for Tonlamarsen in post-hospitalization management of acute severe hypertension, started in June 2026 [catalyst].
- Cash runway and any future financing rounds, given the company's operating losses and reliance on external funding [sec].
- Regulatory and clinical developments for Ataciguat in moderate calcific aortic valve stenosis [sec · filed 2026-06-11].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run Kardigan, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kardigan, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.17 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
3 buys · 0 sells (180d)
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for Kardigan, Inc.?
Kardigan is a clinical-stage precision therapeutics company developing targeted treatments for cardiovascular diseases with no approved therapies, currently advancing three late-stage programs.
Who is the CEO of Kardigan, Inc.?
Mr. Tassos Anastasios E. Gianakakos M.Sc., MBA is the chief executive officer of Kardigan, Inc. (KARD).
Where is Kardigan, Inc. headquartered?
Kardigan, Inc. (KARD) is headquartered in Princeton, NJ, United States.
What therapeutic areas does Kardigan, Inc. focus on?
Kardigan, Inc. develops therapies across Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.